<unk> tion is used to prevent shingles and its complications, including postherpetic neuralgia. It can be considered a therapeutic<unk> , given that it is used to treat a latent virus that has remained dormant in cells since chicken pox infection earlier in life. The two available<unk> s are intended for use in people over the age of 50. it remained to be confirmed whether a booster dose was required, but the Advisory Committee on Immunization Practices (ACIP) in the United States recommends Shingrix for adults over the age of 50, including those who have already received Zostavax. Shingrix Shingrix The ACIP voted that Shingrix is preferred over Zostavax for the prevention of<unk>  and related complications because data showed<unk>  efficacy of more than 90% against shingles across all age groups, as well as sustained efficacy over a 4-year follow-up. Unlike Zostavax, which is given as a single shot, Shingrix is given as two intramuscular doses, two to six months apart. A large randomized clinical trial showed Shingrix reduced the incidence of shingles 96.6% in the 50-59 age group, and 91.3% in those over age 70. The absolute decrease in risk of herpes<unk>  following immunization over three and a half years is 3.3% (3.54% down to 0.28%) while the decrease in the risk of postherpetic neuralgia is 0.3% (0.34% down to 0.06%). Zostavax Zostavax<unk>  A Cochrane review concluded that Zostavax is "effective in preventing herpes<unk>  disease for up to three years". The duration of protection beyond four years after<unk> tion with the<unk>  is unknown. The need for re-vaccination remains to be confirmed. Zostavax was shown to reduce the incidence of shingles by 51% in a study of 38,000 adults aged 60 and older who received the<unk> . The<unk>  also reduced by 67% the number of cases of postherpetic neuralgia (PHN) and reduced the severity and duration of pain and discomfort associated with shingles, by 61%. The FDA originally recommended it for individuals 60 years of age or older who are not severely allergic to any of its components and who meet the following requirements: * do not have a weakened immune system due to HIV/AIDS or another disease or medications (such as steroids, radiation and chemotherapy) that affect the immune system; * do not have a history of cancer affecting the bone marrow or lymphatic system, such as leukemia or lymphoma; and * do not have active, untreated tuberculosis. In 2006, the U.S. Advisory Committee on Immunization Practices (ACIP) recommended that the live<unk>  be given to all adults age 60 and over, including those who have had a previous episode of shingles, and those who do not recall having had chickenpox, since more than 99% of Americans ages 40 and older have had chickenpox.
Zoster vaccine
Polio vaccine
Measles vaccine
Ebola vaccine
Hantavirus vaccine
Typhoid vaccine
DPT vaccine
Varicella vaccine